Showing results (131-140 of 201) with videos related to
Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLCMarius Ilié, Julien Mazières, Emmanuel Chamorey, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.NPJ Precision Oncology|February 16, 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancersMarco Tagliamento, Marie Morfouace, Charalambos Loizides, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 9, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)Chantal Decroisette, Laurent Greillier, Hubert Curcio, et al.Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)Catherine Labbé, Michael Cabanero, Grzegorz J Korpanty, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.Therapeutic Advances in Medical Oncology|May 5, 2021
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasisIsabelle Monnet, Alain Vergnenègre, Gilles Robinet, et al.The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.Pageof 21